Terms: = Ovarian cancer AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p AND Prognosis
12 results:
1. Review on Sertoli-Leydig Cell Tumours of the Ovary.
Muscat C; Calleja-Agius J
Discov Med; 2024 Feb; 36(181):234-247. PubMed ID: 38409829
[TBL] [Abstract] [Full Text] [Related]
2. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
[TBL] [Abstract] [Full Text] [Related]
3. Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in ovarian cancer Patients.
Pawłowska A; Kwiatkowska A; Suszczyk D; Chudzik A; Tarkowski R; Barczyński B; Kotarski J; Wertel I
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768993
[TBL] [Abstract] [Full Text] [Related]
4. Construction of an Immune Cell Infiltration Score to Evaluate the prognosis and Therapeutic Efficacy of ovarian cancer Patients.
Liu J; Wang Y; Yuan S; Wei J; Bai J
Front Immunol; 2021; 12():751594. PubMed ID: 34745124
[TBL] [Abstract] [Full Text] [Related]
5. Progress in the management of ovarian granulosa cell tumor: A review.
Li J; Chu R; Chen Z; Meng J; Yao S; Song K; Kong B
Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1771-1778. PubMed ID: 34027996
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic and Clinical Value of Interleukin 6 and CD45
Wertel I; Suszczyk D; Pawłowska A; Bilska M; Chudzik A; Skiba W; Paduch R; Kotarski J
J Immunol Res; 2020; 2020():1715064. PubMed ID: 33062717
[TBL] [Abstract] [Full Text] [Related]
7. Identification of Candidate Genes Associated with Chemotherapy Resistance in ovarian cancer.
Zhang B; Wang L; Zhao X; Wei Y; Zhang Y
Ann Clin Lab Sci; 2018 Sep; 48(5):573-579. PubMed ID: 30373860
[TBL] [Abstract] [Full Text] [Related]
8. A random forest classifier predicts recurrence risk in patients with ovarian cancer.
Cheng L; Li L; Wang L; Li X; Xing H; Zhou J
Mol Med Rep; 2018 Sep; 18(3):3289-3297. PubMed ID: 30066910
[TBL] [Abstract] [Full Text] [Related]
9. Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of ovarian cancer?
Mittica G; Genta S; Aglietta M; Valabrega G
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27447625
[TBL] [Abstract] [Full Text] [Related]
10. The FOXL2 mutation (c.402C>G) in adult-type ovarian granulosa cell tumors of three Japanese patients: clinical report and review of the literature.
Takahashi A; Kimura F; Yamanaka A; Takebayashi A; Kita N; Takahashi K; Murakami T
Tohoku J Exp Med; 2013 Dec; 231(4):243-50. PubMed ID: 24257635
[TBL] [Abstract] [Full Text] [Related]
11. The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors.
Hamanishi J; Mandai M; Abiko K; Matsumura N; Baba T; Yoshioka Y; Kosaka K; Konishi I
Clin Immunol; 2011 Dec; 141(3):338-47. PubMed ID: 21955569
[TBL] [Abstract] [Full Text] [Related]
12. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer.
Kim H; Scorilas A; Katsaros D; Yousef GM; Massobrio M; Fracchioli S; Piccinno R; Gordini G; Diamandis EP
Br J Cancer; 2001 Mar; 84(5):643-50. PubMed ID: 11237385
[TBL] [Abstract] [Full Text] [Related]
